Methamphetamine abuse in former opiates addicts currently in
International Journal of Applied Behavioral Sciences,
Vol. 2 No. 3 (2015),
20 January 2016
,
Page 29-34
https://doi.org/10.22037/ijabs.v2i3.11201
Abstract
Background: To measure suspected abuse of the methamphetamine (MA) among methadone maintenance treatment (MMT) patients in Tehran, we studied all 206 patients who were admitted to MMT program from 2009 to 2015 to Andishe-No addiction treatment clinic. Methods: MA presence was screened in one of the random urine samples routinely taken for tests of other drugs. Results: 70 (34.3%) patients were positive for MA. A logistic regression (multivariate analyses) demonstrated that the MA abusers were more likely to be opiate abusers and less likely to be married. Conclusion: The high prevalence of MA abuse found in our patients which was rather higher than the rate of MA abuse before treatment entrance. The high rate of MA abuse in Iran needs future study Declaration Interest: None.
- Methamphetamine Abuse
- Opiates Addicts
- Methadone Maintenance Treatment
- Iran
How to Cite
References
Mokri A, Ekhtiari H, Edalati H. Substance abuse disorders and addiction. Iranian Textbook of Psychiatry for Medical Student Tehran: Tehran University of Medical Sciences. 2009.
UNODC. World drug report. United Nations Publication, Sales No. E. 10. XI. 13, New York, NY; 2010.
Nemati Mogadam M. Managing addiction as a chronic condition. J Add. 2008;4:64-7.
Bovasso G, Cacciola J. The long-term outcomes of drug use by methadone maintenance patients. The journal of behavioral health services & research. 2003;30(3):290-303.
Williamson A, Darke S, Ross J, Teesson M. The effect of persistence of cocaine use on 12-month outcomes for the treatment of heroin dependence. Drug and Alcohol Dependence. 2006;81(3):293-300.
UNODC. World Drug Report 2014 By United Nations Office on Drugs and Crime New York: United Nations. 2014.
Mokri A, Schottenfeld R. Drug abuse and HIV transmission in Iran—Responding to the public health challenges. Public health aspects of HIV/AIDS in low and middle income countries: Springer; 2009. p. 583-99.
UNODC. World Drug Report 2007 (United Nations Publication, Sales No. E.07.XI.5). 2007.
Shariatirad S, Maarefvand M, Ekhtiari H. Emergence of a methamphetamine crisis in Iran. Drug and alcohol review. 2013;32(2):223-4.
Shariatirad S, Maarefvand M, Ekhtiari H. Methamphetamine use and methadone maintenance treatment: an emerging problem in the drug addiction treatment network in Iran. Int J Drug Policy. 2013;24:e115-6.
Trujillo KA, Smith ML, Guaderrama MM. Powerful behavioral interactions between methamphetamine and morphine. Pharmacology Biochemistry and Behavior. 2011;99(3):451-8.
McLellan AT, Kushner H, Metzger D, Peters R, Smith I, Grissom G, et al. The fifth edition of the Addiction Severity Index. Journal of substance abuse treatment. 1992;9(3):199-213.
Fureman B, Parikh G, Bragg A, McLellan A. Addiction severity index. A guide to training and supervising ASI interviews (5th ed) University of PA/Philadelphia VAMC, Center for Studies of Addiction. 1990.
Alam-mehrjerdi Z, Mokri A, Dolan K. Methamphetamine use and treatment in Iran: a systematic review from the most populated Persian Gulf country. Asian Journal of Psychiatry. 2015.
Barr AM, Panenka WJ, MacEwan GW, Thornton AE, Lang DJ, Honer WG, et al. The need for speed: an update on methamphetamine addiction. Journal of Psychiatry and Neuroscience. 2006;31(5):301.
Saberi SM, Khodabandeh F, Kahani A, Marashi SM. Delusional Problems and Mood Instability in Acute Psychotic Patients Dependent to Methamphetamine named “Shishe” among Iranian Population. J Addict Res Ther. 2012;3(132):2.
Fasihpour B, Molavi S, Shariat SV. Clinical features of inpatients with methamphetamine-induced psychosis. Journal of Mental Health. 2013;22(4):341-9.
Zarghami M. Methamphetamine has changed the profile of patients utilizing psychiatric emergency services in Iran. Iranian Journal of Psychiatry and Behavioral Sciences. 2011;5(1):1-5.
Batki SL, Harris DS. Quantitative drug levels in stimulant psychosis: relationship to symptom severity, catecholamines and hyperkinesia. American Journal on Addictions. 2004;13(5):461-70.
Callaghan RC, Cunningham JK, Allebeck P, Arenovich T, Sajeev G, Remington G, et al. Methamphetamine use and schizophrenia: a population-based cohort study in California. American Journal of Psychiatry. 2012;169(4):389-96.
Herman BH, Elkashef A, Vocci F. Medications for the treatment of cocaine addiction: Emerging candidates. Drug Discovery Today: Therapeutic Strategies. 2005;2(1):87-92.
Newton TF, Roache JD, De La Garza R, Fong T, Wallace CL, Li S-H, et al. Bupropion reduces methamphetamine -induced subjective effects and cue-induced craving. Neuropsychopharmacology. 2006; 31(7): 1537-44.
Heinzerling KG, Shoptaw S, Peck JA, Yang X, Liu J, Roll J, et al. Randomized, placebo-controlled trial of baclofen and gabapentin for the treatment of methamphetamine dependence. Drug and alcohol dependence. 2006;85(3):177-84.
Johnson BA, Roache JD, Ait-Daoud N, Wells LT, Wallace CL, Dawes MA, et al. Effects of acute topiramate dosing on methamphetamine-induced subjective mood. The International Journal of Neuropsychopharmacology. 2007;10(01):85-98.
Jayaram-Lindström N, Wennberg P, Hurd YL, Franck J. Effects of naltrexone on the subjective response to amphetamine in healthy volunteers. Journal of clinical psychopharmacology. 2004;24(6):665-9.
Rawson R, Obert J, McCann M. The Matrix intensive outpatient program therapist manual. Los Angeles, California: The Matrix Center, lnc. 1995.
Rawson RA, Marinelli‐Casey P, Anglin MD, Dickow A, Frazier Y, Gallagher C, et al. A multi‐site comparison of psychosocial approaches for the treatment of methamphetamine dependence. Addiction. 2004;99(6):708-17.
Bux Jr DA, Irwin TW. Combining motivational interviewing and cognitive-behavioral skills training for the treatment of crystal methamphetamine abuse/dependence. Journal of Gay & Lesbian Psychotherapy. 2006;10(3-4):143-52.
- Abstract Viewed: 353 times
- PDF Downloaded: 305 times